-+ 0.00%
-+ 0.00%
-+ 0.00%

Oculis Gets FDA Clearance to Study Privosegtor in Acute MS Relapses

PUBT·11/16/2026 07:04:24
Oculis Gets FDA Clearance to Study Privosegtor in Acute MS Relapses
  • FDA cleared Oculis' investigational new drug application for Privosegtor, enabling clinical development in acute multiple sclerosis relapses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160200OMX_____CNEWS_EN_GNW1001303703_en) on November 16, 2026, and is solely responsible for the information contained therein.